Product Name：FPV/CPV-2 Injejction
Product Characteristics: Colorless to light yellow clear liquid
Pharmacological Action: This product specifically neutralizes the feline parvovirus (FPV), blocks virus replication， and restores immune
system function， thereby achieving the therapeutic effect on FPV.
Indications： Used for the prevention and treatment of FPV. Especially suitable for cats showing early clinical symptoms (such as vomiting，diarrhea， fever， listlessness， and loss of appetite).
Usage and Dosage：
Administration Route： Intramuscular injection or oral tablet
Dosage: 1 ml per kilogram of body weight (or 1 tablet per kilogram of body weight)
Dosage frequency: Twice daily
Course of treatment: Use continuously without interruption for 3 days.
|
Body Weight (kg)
|
Dose per Administration
|
Daily dosage
|
Total dose on the 3 days
|
|
0.5 kg
|
0.5 ml
|
1.0 ml
|
3.0 ml
|
|
1.0 kg
|
1.0 ml
|
2.0 ml
|
6.0 ml
|
|
1.5 kg
|
1.5 ml
|
3.0 ml
|
9.0 ml
|
|
2.0 kg
|
2.0 ml
|
4.0 ml
|
12.0 ml
|
|
2.5 kg
|
2.5 ml
|
5.0 ml
|
15.0 ml
|
|
3.0 kg
|
3.0 ml
|
6.0 ml
|
18.0 ml
|
|
3.5 kg
|
3.5 ml
|
7.0 ml
|
21.0 ml
|
|
4.0 kg
|
4.0 ml
|
8.0 ml
|
24.0 ml
|
|
4.5 kg
|
4.5 ml
|
9.0 ml
|
27.0 ml
|
|
5.0 kg
|
5.0 ml
|
10.0 ml
|
30.0 ml
|
|
5.5 kg
|
5.5 ml
|
11.0 ml
|
33.0 ml
|
|
6.0 kg
|
6.0 ml
|
12.0 ml
|
36.0 ml
|
|
6.5 kg
|
6.5 ml
|
13.0 ml
|
39.0 ml
|
|
7.0 kg
|
7.0 ml
|
14.0 ml
|
42.0 ml
|
|
7.5 kg
|
7.5 ml
|
14.0 ml
|
45.0 ml
|
|
8.0 kg
|
8.0 ml
|
15.0 ml
|
48.0 ml
|
Clinical data:
According to the results of the multi-center clinical study conducted in China in 2025, it was found that:
If this product is used in the early stage of feline distemper (within 24 hours after the onset of clinical symptoms), the survival rate will exceed 99.5%.
After taking the medicine, no serious adverse reactions were observed.
For the cats that completed the 3-day treatment course consecutively, their clinical symptoms (vomiting, diarrhea, fever) were significantly alleviated, and their white blood cell count returned to the normal range.
Clinical conclusion:
If this product is injected or the oral tablets are administered to cats in the early stage of feline distemper, it can effectively prevent the death of the cats.
Notes:
This product is only applicable to patients in the early stage of feline fever. If the condition has progressed to severe shock, extremely low ody temperature, disseminated intravascular coagulation (DIC), or other terminal stages, the therapeutic effect may be limited.
During use, it is recommended to combine with supportive therapies (such as fluid replacement, temperature maintenance, and electrolyte balance maintenance, etc.).
This product should not be used by those who are allergic to any of its ingredients (the ingredients will be clarified later and a supplement will
be provided).
The safety data for pregnant and lactating cats is not yet sufficient. It is recommended to use under the guidance of a veterinarian.
This product is not applicable for vomiting or leukopenia caused by factors other than feline distemper.
Adverse reactions:
During the clinical study, mild injection site swelling or transient drowsiness was occasionally observed, but no treatment was necessary as
these symptoms would resolve on their own. No serious adverse reactions were noted.
Storage conditions:
Injection: Store refrigerated at 2℃ to 8℃, protected from light, and avoid freezing.
Expiration date: 24 months
For animal use only.
